Pre-Competitive Collaboration Would Help Pharmaceutical Productivity Crisis - If Lawyers Could Get Out Of The Way
CAMBRIDGE, Mass. - Greater R&D collaboration was the theme of the day at the star-studded U.S.-India Chamber of Commerce biopharma and healthcare summit
More from Archive
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
More from Scrip
Japanese CDMO Bushu talks about a consortium designed to provide a broad range of development services to smaller foreign firms looking to bring high-need drugs to the Japanese market.
Cobenfy is approved as a monotherapy, but failed in the adjunctive setting when combined with generic atypical antipsychotics, giving BMS a second Phase III failure in two weeks.
Results from the Phase III HARMONi-6 trial showed the PD-1/VEGF bispecific antibody beating out BeiGene’s Tevimbra in NSCLC.